ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301
October 10, 2020Kodiak Sciences announced the first patients have been treated in the randomized, double-masked GLEAM, GLIMMER and BEACON studies, three pivotal Phase 3 studies of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate ... -
Kodiak Sciences preps $100M IPO to advance AMD drug
September 11, 2018Kodiak's lead asset is designed to have a longer half-life than other anti-VEGF drugs. The hope is to improve patient adherence to a treatment that is injected into the eyes.
Pharma Sources Insight January 2025
